Qol Holdings Co.,Ltd. FY2027 Q1 Earnings Report

Quick View

Executive Summary

The quarter was characterized by higher revenue and earnings, as well as significant profit growth driven by an improvement in the gross margin. The most important point is that profit progress is ahead of the full-year plan. Revenue was ¥739.1B (+3.0% YoY), Operating Income was ¥61.8B (+72.1%), Ordinary Income was ¥61.6B (+69.5%), and Net Income attributable to owners of the parent was ¥30.0B (+61.7%). The gross margin improved to 17.6%, while the SG&A ratio declined to 9.3%, resulting in an expansion of the Operating Income margin to 8.4% (5.0% in the previous year). Although the Pharmaceutical Business’s higher margins drove company-wide earnings, the persistently high tax burden restrained Net Income growth.

Factors Affecting Business Performance

【Revenue】Revenue was ¥739.1B, representing a 3.0% YoY increase. By segment, the Pharmacy Business (HealthInsurancePharmacy) generated ¥437.5B ( +2.1%, 59.2% of total revenue), the Pharmaceutical Business generated ¥263.8B (+3.8%, 35.7%), and the BPO Business generated ¥42.2B (+11.3%, 5.7%). The BPO Business recorded a relatively high growth rate. Revenue from prescription fulfillment increased by ¥40.2B and remained the core source of revenue, while revenue from pharmaceutical manufacturing and sales also increased to ¥26.4B.

【Profit and Loss】Operating Income increased substantially to ¥61.8B (+72.1%), while Ordinary Income rose to ¥61.6B (+69.5%). The primary driver of earnings growth was the expansion of segment profit in the Pharmaceutical Business to ¥49.4B (+113.4%, 18.7% margin), making it the largest contributor to company-wide earnings. In contrast, despite higher revenue, the Pharmacy Business recorded lower profit of ¥16.7B (-4.7%, 3.8% margin), demonstrating a pattern of higher revenue but lower earnings. The BPO Business remained solid at ¥6.5B (+31.6%, 15.4% margin). Extraordinary items were extremely small, with extraordinary losses of ¥0.1B, and the impact of one-time factors was limited. Net Income was limited to ¥30.0B (+61.7%), with the decline from Ordinary Income attributable to the high tax burden (an effective tax rate of approximately 51%). Overall, the company achieved higher revenue and earnings.

Segment Analysis

Segment profit consisted of ¥16.7B for the Pharmacy Business (23.0% of total segment profit, 3.8% margin), ¥49.4B for the Pharmaceutical Business (68.1%, 18.7% margin), and ¥6.5B for the BPO Business (8.9%, 15.4% margin), with the Pharmaceutical Business accounting for approximately 70% of company-wide profit. Operating Income in the Pharmaceutical Business more than doubled, increasing 113.4% from slightly below ¥24.2B in the previous year, while its profit margin also rose substantially. Although revenue in the Pharmacy Business increased 2.1%, profit declined 4.7%, indicating margin pressure under the dispensing fee environment. The BPO Business achieved double-digit growth in both revenue and profit, recording the highest growth rate within the business mix. Company-wide expenses (adjustments) increased from ¥△16.9B in the previous year to ¥△17.9B, with the adjustment equivalent to 14.8% of total segment profit of ¥72.6B.

Key Financial Indicators

【Profitability】The Operating Income margin improved by +336bp to 8.4% (5.0% in the previous year), while the Ordinary Income margin improved to 8.3% (5.1% in the previous year), and the Net Income margin attributable to owners of the parent improved to 4.1% (2.6% in the previous year). The gross margin expanded to 17.6% (14.5% in the previous year), while the SG&A ratio declined to 9.3% (9.5% in the previous year), directly contributing to the improvement in the Operating Income margin. ROE was 6.0%.【Cash Flow Quality】Non-operating income was small at ¥1.7B, and extraordinary items were also insignificant, with extraordinary losses of ¥0.1B. The gap between Ordinary Income and Net Income was primarily attributable to corporate income taxes, and the impact of one-time factors was limited.【Investment Efficiency】The Equity Ratio was 37.6%, broadly unchanged from the previous year. Total assets increased to ¥1636.9B, while intangible fixed assets (¥684.1B, including goodwill of ¥353.7B) accounted for 41.8% of total assets, indicating a high concentration of assets derived from M&A.【Financial Soundness】Long-term borrowings were ¥183.8B and cash and deposits were ¥257.0B. Against interest expense of ¥1.1B, Operating Income of ¥61.8B indicates ample interest-servicing capacity. However, current assets of ¥667.1B compared with current liabilities of ¥795.2B indicate a somewhat tight short-term funding balance.

Cash Flow Analysis

Although detailed disclosure of the statement of cash flows is not available, funding trends can be inferred from changes in the balance sheet. Cash and deposits increased to ¥257.0B, while inventories increased substantially year on year, and accounts receivable and notes receivable remained broadly unchanged at ¥251.2B. Accounts payable and notes payable increased to ¥372.2B, suggesting the use of payment terms associated with expanded procurement. As the increase in inventories may place pressure on working capital, near-term cash generation is considered likely to depend on the turnover efficiency of inventories and accounts receivable. Long-term borrowings were ¥183.8B, broadly unchanged from the previous year, and large-scale financing or repayment activity was limited.

Quality of Earnings

The current period’s earnings growth was primarily driven by an improvement in core operating profit. Extraordinary items were extremely small, consisting of extraordinary income of ¥0.0B and extraordinary losses of ¥0.1B (loss on disposal of fixed assets), indicating that earnings quality is supported by improvement in recurring business activities. Non-operating income was ¥1.7B, including other income of ¥0.3B, compared with non-operating expenses of ¥1.9B, including interest expense of ¥1.1B and handling fees of ¥0.3B, resulting in a slight net excess of expenses. Comprehensive Income was ¥37.1B. The difference between Net Income of ¥30.0B and the ¥37.1B attributable to owners of the parent reflects the impact of ¥7.1B attributable to non-controlling interests. No factors such as valuation differences on securities were observed that would cause a material divergence between Net Income and Comprehensive Income, and no unusual accrual adjustments were identified. The decline from Ordinary Income of ¥61.6B to Net Income of ¥30.0B was primarily due to the corporate income tax burden, with an effective tax rate of approximately 51%. This should be noted as not being a temporary factor arising from the business structure.

Earnings Forecasts and Guidance

The full-year company plan calls for Revenue of ¥3150.0B (+8.3% YoY), Operating Income of ¥165.0B (+11.4%), and Ordinary Income of ¥165.0B (+10.9%). There were no revisions to either the earnings or dividend forecasts during the quarter. Progress rates were 23.5% for Revenue, 37.5% for Operating Income, and 37.3% for Ordinary Income, with progress in Operating Income and Ordinary Income substantially exceeding progress in Revenue. This reflects the high-margin contribution of the Pharmaceutical Business. Based on quarterly progress at this stage, upside to profit forecasts can be inferred, although the sustainability of the Pharmaceutical Business’s profitability throughout the full year will determine future progress.

Shareholder Returns

The company’s full-year dividend plan is ¥54 per share, representing an increase from the previous year’s annual dividend (the sum of interim and year-end dividends; reference data provides partial disclosure, including a previous-year dividend of ¥23). The Payout Ratio against the company’s planned EPS of ¥207.57 is approximately 26.0% (¥54 ÷ ¥207.57), a conservative level. No specific data regarding share repurchases was identified, and shareholder returns currently center on dividends. Given cash and deposits of ¥257.0B and the company’s earnings generation capacity for the current period, there are considered to be no major constraints on dividend sustainability.

Risk Factors

1. Pharmacy Business profitability stagnation: Against revenue growth of +2.1%, the Pharmacy Business recorded a 4.7% decline in Operating Income (3.8% margin), indicating continued margin pressure under the dispensing fee and drug pricing environment. Improving the profitability of this business will be a challenge for smoothing company-wide earnings.

2. Concentration in goodwill and intangible assets: Goodwill of ¥353.7B accounts for 57.5% of net assets of ¥615.4B, while intangible fixed assets of ¥684.1B account for 41.8% of total assets of ¥1636.9B. The high concentration of assets derived from M&A creates a structural impairment risk if business plans are not achieved.

3. High effective tax rate and impact on Net Income: Against Ordinary Income of ¥61.6B, Net Income attributable to owners of the parent was ¥30.0B, resulting in an effective tax rate of approximately 50%, a high level. The heavy tax burden is a structural factor restraining growth in Net Income and ROE.

Industry Benchmark (Reference; Company Analysis)

Industry Benchmark (retail)

Profitability and Returns

The Company’s Operating Income margin and Net Income margin both exceed the industry median, indicating that its profitability is relatively high within the industry.

Growth and Capital Efficiency

The Revenue growth rate is below the industry median, indicating that top-line growth is relatively moderate within the industry.

※Source: Company analysis

Key Points from the Financial Results

1. The Pharmaceutical Business’s higher margins lifted the company-wide Operating Income margin by +336bp, and profit progress against the full-year plan (37.5%) substantially exceeded Revenue progress (23.5%). The extent to which the Pharmaceutical Business’s earnings structure can be sustained will be a key focus going forward.

2. Although the Pharmacy Business achieved higher revenue, its profit margin declined to 3.8%, increasing earnings dependence on the Pharmaceutical Business. The widening margin differential within the business portfolio (18.7% for the Pharmaceutical Business versus 3.8% for the Pharmacy Business) represents an observable change in the earnings structure.

3. The asset composition, in which goodwill and intangible assets account for more than 40% of total assets, reflects an M&A-led growth strategy. At the same time, the persistently high effective tax rate continues to affect Net Income. These are structural characteristics relevant to assessing the quality of the financial results.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly disclosed data using a residual income model (Ohlson type, with an explicit five-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥1,788–¥1,895 at ±1% for the cost of equity, and ¥1,835–¥1,848 at ±0.1 for ω.

Notes:

• Because progress of Net Income against the full-year forecast (38%) exceeds the standard level (25%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies with progress ahead of plan tend to exceed forecasts. The adjustment may be excessive for businesses with strong seasonality).
• Net Income is substantially compressed relative to Operating Income due to the tax burden, acquisition-related expenses, and non-controlling interests (Net Income ÷ Operating Income 47%). This value reflects that compression at face value, and normalized earnings may be higher if the factors are temporary.
• Goodwill represents a high proportion of net assets, and the assumptions would change substantially if impairment occurred.
• Net assets at the end of the quarter are used, resulting in a timing difference relative to the full-year forecast.
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Model: Residual Income Model / Interest rate reference month: 2026-07 / This value is not intended to forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with a professional advisor as necessary.

---End of Report---